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Purpose: To determine the effectiveness and possible side effects of using propranolol for the 
treatment of orbital and periorbital infantile hemangiomas.
Methods: Infants with periorbital or orbital hemangiomas who had not received either local 
or systemic corticosteroids were recruited. The changes in tumor size, color, and texture, and 
any side effects of the drug were recorded.
Results: Fifteen infants with a mean age of 8.13 ± 4.7 months were treated according to 
the set protocol. A change in the color and texture of the hemangioma occurred in the first 
week following treatment. Mean duration of treatment was 7.67 ± 3.96 months. The size of 
hemangiomas decreased from a mean of 2.4 ± 0.9 cm to a mean of 1.6 ± 1.0 cm 3 months after 
treatment (P = 0.001). One patient had to stop the drug because of peripheral vascular ischemia. 
Another case had the dose reduced to control a mild hyperglycemia. Serious side effects were 
not observed. A single case of tumor regrowth (8.3%) was recorded.
Conclusion: Treatment of 1–2 mg/kg/day propranolol proved to be effective and   associated with 
minimal side effects. It is likely to replace steroids as the first-line of treatment of hemangiomas 
in infants.
Keywords: orbital and periorbital hemangioma, β-blockers, propranolol, corticosteroids, 
adrenal suppression
Introduction
Infantile hemangioma (IH) is the most common pediatric tumor, occurring in 5%–10% 
of 1-year-old children, with up to 60% presenting in the head and neck region.1 Large 
hemangiomas can cause amblyopia in up to 60% of cases due to astigmatism or occlusion 
of the visual axis.2 Various modalities have been employed to induce regression in these 
lesions, such as laser therapy, cryotherapy, radiotherapy, injection of sclerosing agents, 
interferon-α, and vincristine,3 but corticosteroids – whether systemic or intralesional – 
remain the mainstay of treatment of IH.4,5 Systemic side effects of corticosteroids have 
been observed following systemic as well as intralesional administration and include 
behavior changes, irritability, insomnia, cushingoid appearance, hypertension, growth 
deceleration, adrenal suppression, and increased susceptibility to infections.6 Local side 
effects include eyelid hypopigmentation,7 subcutaneous fat atrophy,8 and eyelid necrosis.9 
Intralesional injections have also been reported to cause ophthalmic artery or central 
retinal artery occlusions.10 In June 2008, Léauté-Labrèze et al reported an accidentally 
discovered profound regression of a rapidly growing facial hemangioma in a 9-week-
old baby following nonselective β-blocker propranolol administration for a cardiac 





case reports or case series with limited number of infants 
included as well as follow-up interval, and some of the cases 
had already received prior systemic or local corticosteroids at 
some point. Several important questions remained unanswered. 
Are these results reproducible? What is the efficacy of the 
drug? What is the optimal dose, method of initiation, and 
duration of therapy? What about recurrence and possible side 
effects? The purpose of the present study was, therefore, to 
prospectively evaluate the results of this old antihypertensive 
drug as a new first-line of treatment for IH.
Patients and methods
An interventional prospective case series was conducted 
between August 2009 and December 2010 after the approval 
of the local ethics committee and informed consent from the 
legal guardians of the participants were obtained. Inclusion 
criteria were infants newly diagnosed of having periorbital 
or orbital IH, who had not been previously treated with 
local or systemic corticosteroids. In one case of a deep-
seated orbital hemangioma causing proptosis, a biopsy was 
obtained through an inferior transconjunctival orbitotomy 
to confirm the diagnosis before being included. Propranolol 
hydrochloride (PH) was given orally to these infants under the 
supervision of the pediatrician (RG) according to the hospital’s 
safety protocol originally designed for other indications of 
PH administration in infants. Before an infant was given 
PH, a detailed medical history was taken and a complete 
ophthalmic examination performed, followed by physical 
examination and any necessary investigations including 
blood picture, blood glucose, and electrolytes. Infants with 
any systemic diseases, especially respiratory or cardiac 
disease, elevated blood sugar, or other contraindications 
to β-adrenergic blockers, were not recruited. Patients 
were hospitalized and a starting dose of 0.16 mg/kg every 
8 hours before meals was given under close observation. 
If the vital signs and glucose levels remained normal, the 
dose was gradually increased over 2 weeks to 0.67 mg/kg 
every 8 hours (2 mg/kg/day). The commercially available 
preparation Inderal® (AstraZeneca plc, London, UK) as a 
10 mg tablet was used, crushed and dissolved in 10 cc of 
distilled water (1 mg/cc). After the final dose of 2 mg/kg/day 
had been reached (usually within 1–2 weeks), the patient 
was discharged and instructed to visit the outpatient clinic 
every 2 weeks initially, during the first 3 months, then every 
1–2 months. During these visits, the pediatrician would ask 
direct questions about the possible adverse effects of PH, such 
as gastrointestinal or respiratory symptoms; monitor the heart 
rate, blood pressure, blood glucose, and serum electrolytes; 
and perform a thorough clinical examination including 
weighing the infant, and adjusting the dose of PH accordingly. 
Changes in the tumor in terms of color, texture, or size, and 
any side effects of the drug were recorded and documented by 
photograph. A volume estimate of the tumor was determined 
by taking two maximum orthogonal measurements of the 
lesion from the axial computed tomography (CT) scans prior 
to and 3 months after treatment with PH. Subdermal lesions 
were also measured clinically at each visit. The mean of 
the higher figure of the two orthogonal measurements was 
compared prior to, 3, and 6 months after treatment or at the 
end of therapy if earlier. The treatment was discontinued if 
the lesion had completely involuted clinically, if the parents 
decided that the lesion was no longer recognizable and did 
not want to carry on with taking the medication, or if no 
further decrease in size was achieved despite continuation 
of therapy for at least 3 months. PH treatment was tapered 
gradually over 2 weeks. Patients with large hemangiomas 
affecting the eyelid were subjected to amblyopia therapy as 
soon as the visual axis was cleared after prescribing glasses 
for any considerable refractive errors.
Data was analyzed using SPSS/Win statistical pack-
age (v 15; SPSS Inc, Chicago, IL). Numerical data were 
expressed as mean and standard deviation. For quantitative 
data, comparison of repeated measures was done using 
Wilcoxon signed-rank test. A P value ,0.05 was considered 
significant.
Results
Fifteen infants (11 females and 4 males) fit the inclusion 
criteria and were included in this study; their mean age at 
presentation was 8.13 ± 4.7 months. With only one case 
exception, all hemangiomas were subdermal, ie, affecting 
the upper or lower eyelids or both, including the root of the 
nose and sometimes with a superficial element (strawberry 
nevus). In two cases there was an additional involvement of 
the tip of the nose and the lips with similar lesions. A single 
case had a deep orbital lesion.
The tumor responded to the drug and decreased in size in 
all of the cases (100%). A change in color from intense red 
to purple, associated with a palpable softening of the lesion, 
was observed as early as 1 week after PH administration 
(Figures 1 and 2). The visual axis, if initially obliterated, 
was cleared within a few weeks. The mean size of heman-
giomas as measured by CT decreased from 2.4 ± 0.9 cm 
(range 4.0 × 4.0 cm to 1.0 × 0.5 cm) before treatment to a 
mean of 1.6 ± 1.0 cm (range 3.0 × 3.0 cm to 0.25 × 0.25 cm) 
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to involute resulting in a satisfactory cosmetic result in all 
except one case which showed an initially huge hemangioma 
affecting the root of the nose and medial parts of the eyelids 
and orbit which continued to be disfiguring and surgical 
resection of the residual lesion was advocated (Figure 3). 
On CT, the lesion appeared homogenous, showing intense 
enhancement with infusion during the pretreatment prolif-
erative phase and later, with involution, it decreased in size 
and appeared heterogeneous, showing fibrofatty changes 
(Figures 4 and 5). The mean duration of treatment required 
was 7.67 ± 3.96 months and the mean follow-up period 
after propranolol had been stopped was 5.13 ± 3.27 months. 
No serious adverse effects were observed. An acceptable 
decrease in heart rate and blood pressure occurred in all 
patients within the first month (Table 1). These were con-
sidered secondary circulatory system drug effects rather than 
complications and did not require the cessation of therapy. 
Mild hyperglycemia (above 140 mg), confirmed on three 
occasions, was detected in one patient after 2 months of 
treatment and resolved by reducing the dose to 1 mg/kg/day. 
Peripheral vascular ischemic changes in the form of mot-
tling, coldness, and hypoperfusion of the skin of the trunk 
and lower limbs occurred in another case that had no history 
of a vascular disease; PH was stopped and these changes 
resolved completely without sequel (Figure 5). A single 
case (8.3%) showed signs of regrowth after 3 months of 
cessation of therapy: a 12-month-old female who presented 
with subdermal upper-lid hemangiomas was treated with PH 
for 11 months. The lesion considerably decreased in size and 
treatment was terminated upon request of her parents.
Figure 1 A large upper-lid hemangioma prior to and 4 months after treatment.
Figure 2 Multiple facial hemangiomata prior to and 6 months after treatment.
Figure 3 A right upper-lid hemangioma prior to and 3 months after propranolol 
hydrochloride administration with an evident decrease in size as shown by the axial 
computed tomography scan with enhancement.
Figure  4  A  2-week-old  girl  with  a  right  deep  orbital  hemangioma  causing 
proptosis prior to and 3 months after treatment; computed tomography scan with 
enhancement shows a change in the size and appearance of the lesion being initially 
homogenous  in  the  proliferative  phase,  then  becoming  heterogenous  denoting 





of placental cells into the circulation that might embolize 
to fetal vascular sites has been proposed.14 In favor of this 
placental hypothesis are the recent reports of increased inci-
dence of IH associated with chorionic villus sampling, but 
not with amniocentesis,15 and the demonstration that both 
IH endothelium and placental vessels share the expression 
of several surface markers as glucose transporter 1, which 
is not found in other vascular tumors or malformations, nor 
normal skin.14
The proliferation and involution of hemangiomas are 
controlled by complex interactions of molecular, cellular, 
and hormonal regulators. Takahashi et al hypothesized that 
during the third trimester of fetal development, masses of 
plump immature endothelial cells coexist with immature 
pericytes, which maintain their proliferative capacity for a 
limited period during postnatal life.16 Angiogenic peptides, 
such as β-fibroblast growth factor, vascular endothelial 
growth factor, and proliferating cell nuclear antigen, induce 
proliferation of these immature cells, resulting in the develop-
ment of the hemangioma. As the endothelial cells differenti-
ate, an influx of mast cells, various myeloid cells, and tissue 
inhibitors of metalloproteinases occurs. Tissue inhibitors 
of metalloproteinases, along with interferon and transform-
ing growth factor produced by the mast cells, terminate 
the endothelial cell proliferation and induce involution by 
apoptosis of endothelial cells.17
In view of the new theories for pathogenesis, possible 
explanations for the therapeutic effect of such β-blockers 
as propranolol on IH may include vasoconstriction due to 
decreased release of nitric oxide, which results in the early 
visible change in color and is associated with a palpable 
softening of the hemangioma.18 Decreased expression of 
proangiogenic factors like vascular endothelial growth 
factor and β-fibroblast growth factor may occur through 
the down regulation of the Raf-mitogen-activated protein 
kinase pathway,19 matrix metallopeptidase 9 secretion, and 
human brain microvascular endothelial cells tubulogenesis,20 
which explains the progressive improvement of the heman-
gioma, possibly through the triggering of apoptosis of 
capillary endothelial cells, which results in further tumor 
involution.21
Pediatricians recite a long list of possible side effects 
of β-blockers including fatigue, gastrointestinal upset, 
nightmares, anxiety, dizziness, and bronchospasm, as 
well as hyperlipidemia and hyperglycemia.  22 Thus, they 
are relatively contraindicated in children with asthma or 
diabetes. β-blockers may also predispose young children, 
Figure 5 Thigh of a 2-month-old child showing peripheral vascular ischemic changes 
at 3 weeks from propranolol hydrochloride administration; mottling became more 
apparent after 4 weeks. These changes were reversible.
Table 1 Changes in size, heart rate, blood pressure, and blood 
glucose prior to and 3 months after treatment
Pretreatment After  
3 months
P value
Largest diameter (cm)     2.4 ± 0.9     1.6 ± 1.0 0.001
heart rate  
(beats/minute)
104.3 ± 9.4   93.4 ± 6.8 0.001
systolic blood pressure  
(mmhg)
111.7 ± 13.1   92.1 ± 6.7 0.001
Diastolic blood pressure  
(mmhg)
  68.2 ± 10.8   57.9 ± 7.8 0.007
Blood glucose (mg/dL) 114.0 ± 20.6 115.8 ± 14.8 0.300
Discussion
This is one of few prospective studies concerning the use 
of oral PH for the treatment of IH that was preceded by or 
accompanied with administration of corticosteroids. No treat-
ment failure was observed in any patients in this study who 
were able to continue the administration of PH (14 patients). 
PH proved to be well tolerated, safe, and without considerable 
complications when used in infants.
All other current drug-based therapeutic options for 
IH, similar to steroids, have been known to cause serious 
complications in the pediatric population. Therapy with 
immunomodulators such as cyclophosphamide or vincristine 
has been associated with myelosuppression and hepatotoxic 
effect. Also, serious neurotoxic effects in the form of spastic 
diplegia in up to 20% of cases were reported when interferon-
α2a was used in treatment of IH.12
Recently, new molecular and cellular insights have helped 
in understanding the pathophysiology of IH. An intrinsic 
defect in endothelial cells caused by a genetic mutation of the 
endothelial cell or its progenitor has been suggested;13 another 
theory involves the hypoxia-inducible factor 1a, a major 
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especially infants, to hypoglycemia with even masking of 
the β-sympathetic-related symptoms,23 but this has been 
reported mainly in circumstances of diminished feeding. 
This was avoided in the authors’ study by ensuring that 
children were well fed during drug therapy. The occurrence 
of a reversible peripheral vascular ischemic-like change that 
was not linked to any original disease and, therefore, had to 
be linked to the administration of PH is reported for the first 
time in this study.
Although partial regrowth of the tumor has been 
commonly reported with oral corticosteroids,24 to the 
authors’ knowledge, previous studies have not mentioned the 
regrowth of the hemangioma after stopping PH except in a 
single study in which a recurrence of the hemangioma within 
8 weeks of stopping the drug was reported in two patients 
when PH was given for a short duration and was tailed down 
rapidly.25 In this study, however, a single case (8.3%) showed 
signs of regrowth of the hemangioma 3 months after PH 
administration had been stopped. The reason for this was 
possibly the cessation of therapy while the tumor still had 
proliferating cells. A longer follow-up period of a greater 
number of patients treated with PH is needed before reaching 
a conclusion in this matter.
Conclusion
A PH dose between 1–2 mg/kg/day for 6 to 12 months is 
both effective and safe for the treatment of IH. However, 
a collaborative approach with a pediatrician is required. 
A pretreatment work up and gradual loading and tapering 
with close monitoring on an outpatient basis during the initial 
phase of treatment is recommended. The use of PH would be 
extremely beneficial in multiple and miliary hemangioma-
tosis and in deep orbital lesions where surgical excision or 
steroid injections are hazardous. β-blockers may well replace 
corticosteroids as the first-line of treatment for IH with 
improved tolerability and side-effect profile. In the future, 
steroid use can be limited to cases of allergy, resistance, or 
contraindications to β-blockers.
Acknowledgment
The authors appreciate the consent of the guardians of 
those cases whose photos were used in this report so as 
not to mask their features to help show clearly the effect 
of treatment.
Disclosure
The authors report no conflicts of interest in this work.
References
  1.  Powell J. Update on hemangiomas and vascular malformations. Curr 
Opin Pediatr. 1999;11(5):457–463.
  2.  Schwartz SR, Blei F, Ceisler E, Steele M, Furlan L, Kodsi S. Risk 
factors for amblyopia in children with capillary hemangiomas of the 
eyelids and orbit. J AAPOS. 2006;10(3):262–368.
  3.  Frieden IJ, Haggstrom AN, Drolet BA, et al. Infantile hemangiomas: 
current knowledge, future directions. Proceedings of a research 
workshop on infantile hemangiomas, April 7–9, 2005, Bethesda, 
Maryland, USA. Pediatr Dermatol. 2005;22(5):383–406.
  4.  Chowdri NA, Darzi MA, Fazili Z, Iqbal S. Intralesional corticosteroid 
therapy for childhood cutaneous hemangiomas. Ann Plast Surg. 1994; 
33(1):46–51.
  5.  Orawiec B, Stefanczyk L, Czajkowski J, Bogorodzki B. Gralek M. 
  Periorbital capillary hemangiomas in children–treatment and monitoring 
of treatment. Klin Oczna. 1996;98(3):217–220. Polish.
  6.  George ME, Sharma V, Jacobson J, Simon S, Nopper AJ. Adverse 
effects of systemic glucocorticosteroid therapy in infants with 
  hemangiomas. Arch Dermatol. 2004;140(8):963–969.
  7.  Cogen MS, Elsas FJ. Eyelid depigmentation following corticosteroid 
injection for infantile ocular adnexal hemangioma. J Pediatr Ophthalmol 
Strabismus. 1989;26(1):35–38.
  8.  Townshend LM, Buckley EG. Linear subcutaneous fat atrophy after a 
single corticosteroid injection for ocular adnexal hemangioma. Am J 
Ophthalmol. 1990;109(1):102–103.
  9.  Sutula FC, Glover AT. Eyelid necrosis following intralesional 
corticosteroid injection for capillary hemangioma. Ophthalmic Surg. 
1987;18(2):103–105.
  10. Kushner BJ, Lemke BN. Bilateral retinal embolization associated 
with intralesional corticosteroid injection for capillary heman-
gioma of infancy. J Pediatr Ophthalmol Strabismus. 1993;30(6): 
397–399.
  11.  Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, Boralevi F, 
Thambo JB, Taieb A. Propranolol for severe hemangiomas of infancy. 
N Engl J Med. 2008;358(24):2649–2651.
  12.  Barlow CF, Priebe CJ, Mulliken JB, et al. Spastic diplegia as a 
  complication of interferon alfa-2a treatment of hemangiomas of infancy. 
J Pediatr. 1998;132(3 Pt 1):527–530.
  13.  Ritter MR, Butschek RA, Friedlander M, Friedlander SF. Pathogenesis 
of infantile haemangioma: new molecular and cellular insights. Expert 
Rev Mol Med. 2007;9(32):1–19.
  14.  North PE, Waner M, Mizeracki A, et al. A unique microvascular 
  phenotype shared by juvenile haemangiomas and human placenta. Arch 
Dermatol. 2001;137(5):559–570.
  15.  Burton BK, Schulz CJ, Angle B, Burd LI. An increased incidence of 
hemangiomas in infants born following chorionic villous sampling 
(CVS). Prenat Diagn. 1995;15(3):209–214.
  16.  Takahashi K, Mulliken JB, Kozakewich HP, Rogers RA, Folkman J, 
  Ezekowitz RA. Cellular markers that distinguish the phases of heman-
gioma during infancy and childhood. J Clin Invest. 1994;93(6): 
2357–2364.
  17.  Ritter MR, Reinisch J, Friedlander SF, Friedlander M. Myeloid cells 
in infantile hemangioma. Am J Pathol. 2006;168(2):621–628.
  18.  Shyu KG, Liou JY, Wang BW, Fang WJ, Chang H. Carvedilol prevents 
cardiac hypertrophy and overexpression of hypoxia-inducible factor-1 
and vascular endothelial growth factor in pressure-overloaded rat heart. 
J Biomed Sci. 2005;12(2):409–420.
  19.  D’Angelo G, Lee H, Weiner RI. cAMP-dependent protein kinase 
inhibits the mitogenic action of vascular endothelial growth factor and 
fibroblast growth factor in capillary endothelial cells by blocking Raf 
activation. J Cell Biochem. 1997;67(3):353–366.
  20.  Annabi B, Lachambre MP, Plouffe K, Moumdjian R, Beliveau R. 
Propranolol adrenergic blockade inhibits human brain endothelial cells 
tubulogenesis and matrix metalloproteinase-9 secretion. Pharmacol 
Res. 2009;60(5):438–445.Clinical Ophthalmology
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/clinical-ophthalmology-journal
Clinical Ophthalmology is an international, peer-reviewed journal 
covering all subspecialties within ophthalmology. Key topics include: 
Optometry; Visual science; Pharmacology and drug therapy in eye 
diseases; Basic Sciences; Primary and Secondary eye care; Patient 
Safety and Quality of Care Improvements. This journal is indexed on 
PubMed Central and CAS, and is the official journal of The Society of 
Clinical Ophthalmology (SCO). The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.






  21.  Sommers Smith SK, Smith DM. Beta blockade induces apoptosis in 
cultured capillary endothelial cells. In Vitro Cell Dev Biol Anim. 2002; 
38(5):298–304.
  22.  Wiysonge C, Bradley H, Mayosi B, et al. Beta-blockers for hypertension. 
Cochrane Database Syst Rev. 2007;1:CD002003.
  23.  Chavez H, Ozolins D, Losek JD. Hypoglycemia and propranolol 
in   pediatric behavioral disorders. Pediatrics. 1999;103(6 Pt 1): 
1290–1292.
  24.  Abry F, Kehrli P, Speeg-Schatz C. Hemangioma of the eyelids and 
orbit in children: therapeutic follow-up. J Fr Ophthalmol. 2007;30(2): 
170–176. French.
  25.  Chik KK, Luk CK, Chan HB, Tan HY. Use of propranolol in infantile 
haemangioma among Chinese children. Hong Kong Med J. 2010;16(5): 
341–346.